Annexon reports inducement grants to new employees under nasdaq listing rule 5635(c)(4)

Brisbane, calif., dec. 16, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 employment inducement award plan. the equity awards were approved on december 10, 2024, in accordance with nasdaq listing rule 5635(c)(4).
ANNX Ratings Summary
ANNX Quant Ranking